Fireside chat between Hal Barron and John Carroll, UKBIO19
October 5, 2022 07:38 AM EDT
Bioregnum

It’s time we talked about bio­phar­ma — live in Lon­don next week

John Carroll

Editor & Founder

Zoom can on­ly go so far. And I think at this stage, we’ve all test­ed the lim­its of stay­ing in touch — vir­tu­al­ly. So I’m par­tic­u­lar­ly …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times